SCHEMBL4809728

SCHEMBL4809728

CCOC(=O)CC(=NOC)c1ccc(OC)cc1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.51
GAA P10253 1/20 0.51
KMT2A Q03164 3/20 0.49
MAPT P10636 2/20 0.49
HPGD P15428 1/20 0.49
HDAC3 O15379 3/20 0.47
HDAC1 Q13547 3/20 0.47
HDAC2 Q92769 3/20 0.47
PKM P14618 2/20 0.47
HDAC4 P56524 2/20 0.47
HDAC7 Q8WUI4 2/20 0.47
HDAC10 Q969S8 2/20 0.47
HDAC11 Q96DB2 2/20 0.47
HDAC8 Q9BY41 2/20 0.47
HDAC6 Q9UBN7 2/20 0.47
HDAC9 Q9UKV0 2/20 0.47
HDAC5 Q9UQL6 2/20 0.47
MEN1 O00255 1/20 0.46
CA1 P00915 2/20 0.45
CA2 P00918 2/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4809724 1.00 ALDH1A1 (0.51) ALDH1A1GAAKMT2AMAPTHPGD
SCHEMBL5148094 0.85 GAA (0.54) ALDH1A1GAAKMT2AMAPTMEN1
SCHEMBL8063117 0.83 MAPT (0.51) ALDH1A1MAPTHDAC3HDAC1HDAC2
SCHEMBL4806906 0.81 ALDH1A1 (0.52) ALDH1A1GAAKMT2APKMMEN1
SCHEMBL4806901 0.81 ALDH1A1 (0.52) ALDH1A1GAAKMT2APKMMEN1
SCHEMBL9180317 0.80 MAPT (0.47) ALDH1A1GAAKMT2AMAPTHPGD
SCHEMBL9180324 0.80 MAPT (0.47) ALDH1A1GAAKMT2AMAPTHPGD
SCHEMBL314216 0.80 HDAC3 (0.60) ALDH1A1KMT2AMAPTHPGDHDAC3
SCHEMBL25917253 0.79 CTSK (0.53) ALDH1A1GAAKMT2AMAPTHPGD
SCHEMBL9516341 0.78 ALDH1A1 (0.43) ALDH1A1GAAKMT2AMAPTHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7390925-B2 Oxime-containing acyl guanidines as beta-secretase inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2008-06-24 US disclosed
US-7390925-B2 Oxime-containing acyl guanidines as beta-secretase inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2008-06-24 US disclosed
US-20070232581-A1 Oxime-Containing Acyl Guanidines as Beta-Secretase Inhibitors BRISTOL-MYERS SQUIBB COMPANY 2007-10-04 US disclosed
US-20070232581-A1 Oxime-Containing Acyl Guanidines as Beta-Secretase Inhibitors BRISTOL-MYERS SQUIBB COMPANY 2007-10-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070232581-A1 Oxime-Containing Acyl Guanidines as Beta-Secretase Inhibitors BACE1, APP, BACE2 ALDH1A1 1599/4885GAA 70/4885KMT2A 2775/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.